SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Alumis (ALMS) is trending significantly higher after announcing positive Phase 3 clinical trial results for its oral TYK2 inhibitor, envudeucitinib, in moderate-to-severe plaque psoriasis, demonstrating high rates of skin clearance. This strong efficacy has ignited community discussions, with many anticipating substantial price appreciation and the potential for a significant short squeeze in the large dermatology market. Conversely, a skeptical segment warns of possible dilution through a secondary offering or a typical biotech "pump and dump" scenario post-news.

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in Chicago, IL.

Bright Minds Biosciences Inc

Bright Minds Biosciences (DRUG) is trending following positive preliminary Phase 2 clinical trial results for its BMB-101 epilepsy treatment, which the community is widely discussing as a significant breakthrough. Enthusiasm is driving speculative conversation around the drug's potential, with many comparing its anticipated growth to prior high-flying biotech stocks, though some caution against rapid price swings.

PMGC Holdings, Inc. is a physician-dispensed skincare company, which engages in the research and development of skincare formulations. It is involved in the production and commercialization of topical skincare products that contain its proprietary stem cell-derived Elevai Exosomes. The company was founded by Hatem Abou-Sayed, Braeden William Lichti, and Jordan R. Plews on June 9, 2020 and is headquartered in Newport Beach, CA.

PMGC Holdings Inc

PMGC Holdings Inc.

ELAB is trending following a recent reverse stock split that significantly reduced its public float, amplifying short squeeze speculation, alongside news of strategic acquisitions in nuclear energy and a subsidiary achieving aerospace certification. Community discussions are sharply divided, with many highlighting the stock's extremely high cost-to-borrow and zero shares available for shorting as catalysts for a major upward move, while others caution against its history of dilution and label it a speculative pump-and-dump play.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending following a wave of analyst upgrades, with several firms designating it a "Top Pick for 2026" and raising outlooks, fueling optimism for a multi-year recovery. The community is sharply divided, with bulls viewing UNH as a defensive safe haven amidst broader market shifts, while bears anticipate continued volatility due to ongoing regulatory scrutiny and healthcare policy debates.

Memecoin on Injective taken over by the community.

Nonja

NONJA CRYPTO is trending as a key leveraged play within the Injective ($INJ) ecosystem, benefiting from Injective's strong fundamentals, high developer activity, and anticipated institutional interest. The community is actively discussing $NONJA's robust organic growth, high burned liquidity, unique NFT collections, and its potential for substantial gains as Injective continues to expand.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is actively trending amidst a notable price increase and rising trading volume, sparking intense debate within the crypto community. Supporters highlight its foundational utility in decentralized data and IoT, alongside its regulatory compliance in Japan, as key long-term drivers. However, skeptics remain vocal, pointing to historical drawdowns and questioning the sustainability of recent rallies, with many viewing it as a speculative trading asset rather than a stable investment.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy Inc. is trending due to significant developments, including executing a Department of Energy agreement for its Project TETRA and expanding its contract with Westinghouse for advanced nuclear fuel plants. The community is actively discussing IMSR's potential as an undervalued player in the growing clean energy sector, often comparing its integral molten salt reactor technology to peers like OKLO in the context of increasing demand for reliable power and industrial heat.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending due to its announced strategic collaboration with OpenAI, integrating advanced AI models into its Athena marketing platform. This partnership is generating significant community excitement, with many viewing it as a transformative move from ad-tech to AI-enabled enterprise software, positioning ZETA for a potential breakout and a re-rating within the broader AI sector.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is generating significant buzz, fueled by substantial ETF inflows and growing institutional interest, which some interpret as a sign of its increasing utility and potential decoupling from Bitcoin. The community is actively discussing a robust upward trend, with many anticipating continued gains driven by these developments and future regulatory clarity.

Aeva Technologies, Inc. develops sensing paradigm for autonomous vehicles and robotics. The firm offers drones, robotics, vehicle technology, and virtual and augmented reality products. The company was founded by Soroush Salehian Dardashti and Mina Rezk in 2017 and is headquartered in Mountain View, CA.

Aeva Technologies Inc

The community is buzzing following news of Aeva Technologies integrating its 4D LiDAR as a reference sensor within NVIDIA's DRIVE Hyperion platform. This significant partnership, alongside Aeva's unveiling of its new Omni 4D LiDAR sensor developed with LG Innotek at CES, is fueling bullish speculation about its role in autonomous driving and physical AI applications. Investors are actively discussing its advanced FMCW technology and potential for future growth, despite some acknowledging the longer-term production timeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AMRN I noticed there are only 20 people registered for Dr Bhatt’s talk this afternoon and 2 of them are “employees of AMGEN” hmmm. Both are “Medical Science Liason”. Why is Amgen so interested in Amarin’s drug being effective for treating Covid??????

LJOHN484

1of789

Sieppo

Jay G

Steve Rodgers

ONCEINALIFETIME

Michael Henderson

jay spinelli

Iryokabu

Steve Rogers

Anil

Who_is_JohnnyGalt

ShortFishFry

sanam

Kishore Rachamalla

Bruce Lee

Amit Khatkar

StockTwits for iOS

Amarin Corp - ADR

 I noticed there are only 20 people registered for Dr Bhatt’s talk this afternoon and 2 of them are “employees of AMGEN” hmmm. Both are “Medical Science Liason”. Why is Amgen so interested in Amarin’s drug being effective for treating Covid??????

Mark Brady

@Pharmacydude can we see that info too? Is that a low number?

 can we see that info too? Is that a low number?

@Gaar https://nlasessions.pathable.co/meetings/PAfjHhtXbyGSwiycS#/?limit=10&amp;sortByFields[0]=isPinned&amp;sortByFields[1]=lastActivityAt&amp;sortByOrders[0]=-1&amp;sortByOrders[1]=-1&amp;uid=peTero2J6SWhrB5Cb

Pathable

@Pharmacydude 20 seems like a pretty light number?

Sweaty Tricks

@Pharmacydude Lets be real ... they could be there for the free pens and stress balls they give out.

Bill

edward

StockTwits For Android 

 Lets be real ... they could be there for the free pens and stress balls they give out.

Rai Den

@VascepaBID It’s a virtual conference. They don’t get anything

 It’s a virtual conference. They don’t get anything

@Pharmacydude @Gaar 20 is too low.. can’t read too much into attending 2 people being from same company

 20 is too low.. can’t read too much into attending 2 people being from same company

Brad

@Bradicelandic @Gaar perfect comarketing product for Repatha. Amgen has a great PCSK9 to lower LDL and there revenue is falling hard lately so they desperately need a new blockbuster

morisboris

Kim Frazier

 perfect comarketing product for Repatha. Amgen has a great PCSK9 to lower LDL and there revenue is falling hard lately so they desperately need a new blockbuster

@Pharmacydude Wondering if they need a replacement for heart drug medicine.  In November they ended collaboration with Cytokinetics.

 Wondering if they need a replacement for heart drug medicine.  In November they ended collaboration with Cytokinetics.

Buy the fear!

@Pharmacydude @Gaar every BP has a product which can be matched with Vascepa . I’m not trying to undermine the great work you are doing , it’s just that we can’t read too much . I would be glad if Amgen buys , thanks for all your dd .

 every BP has a product which can be matched with Vascepa . I’m not trying to undermine the great work you are doing , it’s just that we can’t read too much . I would be glad if Amgen buys , thanks for all your dd .

@Bradicelandic @Gaar Sorry!!!! Everyone. False alarm. There are 3 trials. 2 are EPA and one is inclisiran (a competitor of Amgen’s Repatha). The 2 Amgen people are registered for all 3 presentations and are likely just there to check out their competition. $AMRN

 Sorry!!!! Everyone. False alarm. There are 3 trials. 2 are EPA and one is inclisiran (a competitor of Amgen’s Repatha). The 2 Amgen people are registered for all 3 presentations and are likely just there to check out their competition. 

@Pharmacydude they need drug portfolio help by the way....they are actively looking for companies to acquire one rumor was $srne Sorrento Pharmaceuticals as well. They are way behind the eightball for covid.

Sorrento Therapeutics Inc

 they need drug portfolio help by the way....they are actively looking for companies to acquire one rumor was 

 Sorrento Pharmaceuticals as well. They are way behind the eightball for covid.